Crossmark

Letter to the editor about the article “Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study”

Crossref DOI link: https://doi.org/10.1007/s00198-022-06582-w

Published Online: 2022-11-15

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Daly, Robin M. https://orcid.org/0000-0002-9897-1598
Scott, David

Mesinovic, Jakub

Beck, Belinda R.
License Information

Text and Data Mining valid from 2022-11-15

Version of Record valid from 2022-11-15
More Information

Article History

Received: 4 September 2022

Accepted: 19 October 2022

First Online: 15 November 2022

Declarations

:

: RMD reports funding from competitive grants from Amgen-Osteoporosis Australia-Australian and New Zealand Bone and Mineral Society and funding from Fonterra Co-operative Group Ltd., and honoraria for presentations on non-pharmacological approaches from Amgen Australia, Abbott Australia and Nutricia Research; DS reports funding from a competitive Amgen-Osteoporosis Australia-Australian and New Zealand Bone and Mineral Society research grant and honoraria for presentations on non-pharmacological approaches from Amgen Australia; BRB is the owner and Director of The Bone Clinic, Brisbane, QLD and has received funding from a competitive Amgen-Osteoporosis Australia-Australian and New Zealand Bone and Mineral Society research grant and honoraria for presentations on non-pharmacological approaches from Amgen Australia. JM declares no competing interests.

Document is current

Any future updates will be listed below